1. Cancer peptide vaccine designed to stimulate the patient’s immune system to attack cancer cells
  2. HLA-A2-restricted peptides covering ~50% of the USA and EU populations
  3. Assuming use in combination with an immune checkpoint inhibitor
  4. Clinical studies on melanoma and NSCLC ongoing in the USA
Combination treatments of cancer immunotherapy

Combination treatments of cancer immunotherapy

GRN-1201 is a novel cancer peptide vaccine and targets four novel tumor-associated antigens that are shared across major cancer types. The peptides of GRN-1201 are restricted to HLA-A2, which includes approximately 50% of the populations of the USA and Europe, as well as 40% of the population of JP. An open-label phase I clinical study on melanoma and a phase II clinical study in combination with an immune checkpoint inhibitor on non-small cell lung cancer are ongoing in the USA.

The development of GRN-1201 is focused on combination treatments with other and other immune checkpoint inhibitors such as anti-PD-1-blocking antibodies.

The immune system distinguishes between normal cells (self) and those it sees as “foreign” cells, which trigger the immune system to attack the foreign cells only. The trigger depends on “checkpoints” – molecules on certain immune cells that need to be activated (or inactivated) to initiate an immune response. Cancer cells sometimes utilize “brake” type checkpoints, which normally function to prevent the immune system from attacking normal cells in the body, to escape immune attack. Immune checkpoint inhibitors block the “brake,” that is, the binding of checkpoint molecules on immune cancer cells, and unleash the immune response to kill the cancer cells. With their remarkable clinical outcomes, immune checkpoint blockades have been remodeling the cancer-treatment landscape.

However, the response rate to these immune checkpoint inhibitors as monotherapy is reported to be 10–40%, depending on cancer type and stage, which means that a sufficient therapeutic effect is not achieved in 60–90% of patients. One reason for this low effective rate is an inadequate capacity to induce the immune system to eliminate cancer due to an insufficient supply of high-immunogenicity cancer antigens. In order for an immune checkpoint inhibitor to work effectively in the strongly immunosuppressive tumor microenvironment, it is crucial to infiltrate the tumor site with abundant cytotoxic T cells.

The functions of a cancer vaccine are to boost the immune response to TAAs and increase the activation of tumor-specific T cells, which infiltrate the tumor site and eliminate cancer cells. Therefore, cancer vaccines and immune checkpoint inhibitors are complementary, and the combination has the potential for synergistic effects. Further improvement of the efficacy of cancer immunotherapy can be expected using our product in combination with immune checkpoint inhibitors.

To assess their potentiality, a phase II clinical study combining GRN-1201 with a checkpoint inhibitor in non-small cell lung cancer is ongoing.